Background. Rapid diagnosis and treatment of meningitis and encephalitis is critical to reduce morbidity and mortality. The Biofire FilmArray Meningitis/ Encephalitis (ME) Panel is a rapid, multiplex PCR assay that targets 14 common bacterial, viral, and fungal agents of ME. To our knowledge, there are no published studies evaluating the ME Panel's impact on clinical decision-making.
Background. Polymyxin resistance among Enterobacteriaceae is increasingly reported worldwide, with plasmid-mediated colistin resistance, conferred by mcr-1, recently reported. In 2017, CLSI set colistin Epidemiological Cutoff Values (ECVs) for Enterobacteriaceae. There are limited accurate methods for colistin susceptibility testing. The new rapid polymyxin NP (PBNP) test detects bacterial growth in the presence of colistin. We evaluated AD and BMD in comparison to PBNP using clinical isolates of Enterobacteriaceae, which we also tested for mcr-1. We additionally gathered colistin MIC data among Enterobacteriaceae isolates over a period of 6 years.
Methods. Colistin MICs were determined by BMD and AD for 100 clinical isolates of Enterobacteriaceae submitted to our laboratory from August 2016 to February 2017. mcr-1 testing was performed via a laboratory developed real-time PCR assay on a LightCycler 480 platform. PBNP was also performed. Colistin MIC distributions, determined using AD, were reviewed for all isolates of Enterobacteriaceae submitted to our laboratory from 2011 to 2017 after excluding species with intrinsic resistance to colistin.
Results. With BMD as the reference method, the essential and categorical agreement of AD was 86.3 and 97.7%, respectively. The very major and major error rates for AD were 2.5% (1/40) and 2.9% (1/34), respectively. Sensitivity and specificity of PBNP were 90.7 and 94.1%, respectively. One isolate tested positive for mcr-1 (Escherichia coli, MIC 4 µg/mL by AD and BMD and positive PBNP). Excluding species with intrinsic resistance to colistin, 1153/48,441 isolates (2.4%) had colistin MICs ≥ 4 µg/mL by AD. Enterobacter cloacae complex, Klebsiella pneumoniae and E. coli were the most common species with colistin MICs ≥ 4 µg/mL (by AD). 2.7% (31/1153) of isolates with colistin MICs ≥ 4 µg/mL (by AD) were also resistant to a carbapenem; K. pneumoniae was the most common species with concomitant colistin MICs ≥ 4 µg/mL by AD and carbapenem resistance.
Conclusion. A low percentage of isolates surveyed over the past 6 years demonstrated elevated MICs to colistin by AD. AD did not meet essential agreement criteria for colistin susceptibility testing. PBNP was found to have good sensitivity and specificity when compared with BMD.
Background. Contaminated blood cultures are a particular problem in EDs and often lead to unnecessary antibiotic treatment. A potential approach to reduce contamination is to discard the initial aliquot of blood which is often contaminated with skin plugs and bacteria. To test this approach, we performed a study using the Steripath® (SP) device (Magnolia Medical Technologies, WA) a pre-assembled, sterile blood culture system designed to divert the initial 1.5-2.0 mls of blood prior to bottle inoculation.
Methods. This was a pre-post intervention study conducted in the ED at Rush University Medical Center, Chicago. During the pre-intervention phase (1 September to 30 November 2015), 2 sets of peripheral blood cultures were collected using standard aseptic technique by nurses in the ED. Skin antisepsis was performed with ChloraPrep® and 5-10 mls of blood was inoculated into BacT Alert SA and SN bottles (Biomerieux). During the intervention phase (1 February to 1 May 2016), blood cultures were collected using the SP device. All bottles were incubated for 5 days and rates of blood culture contamination were compared between control and intervention periods.
Results. Classification of blood culture contamination was based on standard CLSI criteria. During the control phase, 929 sets of blood cultures were collected in the ED. A total of 40/929 sets (4.3%) from 36 patients were identified as contaminations and 81 sets (8.7%) from 51 patients were identified as true bacteremia. The contaminants included: 29 sets (72.5%) coagulase negative Staphylococcus spp. (CoNS), 4 sets (10%) Micrococcus spp., 3 sets (7.5%) Corynebacterium spp., 2 sets (5%) alpha-hemolytic Streptococci spp., 1 set (2.5%) each Bacillus spp. and E. faecium. During the intervention phase, 3/539 (0.6%) sets of blood cultures from 3 patients were contaminated (P < 0.001). The 3 contaminants were 1 CoNS, 1 alpha-hemolytic Streptococcus spp. and 1 Corynebacterium spp. 49 sets (9.1%) from 35 patients were identified as true bacteremia.
Conclusion. The use of the SP device in the ED over a 3-month period significantly reduced the rate of blood culture contamination from 4.3% to 0.6% while the rates of true bacteremia remain unchanged. The SP device represents a simple and effective method for reducing blood culture contamination Disclosures. All authors: No reported disclosures.
